ischemia |
Manually Genotype(Total Text Mining Genotypes:0) |
---|
(Waiting for update.) |
All Snps(Total Genotypes:4) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
rs11549029 | 18790732 | 126393 | HSPB6 | umls:C0022116 | BeFree | To examine the potential functional significance of the P20L-Hsp20 human variant, adult rat cardiomyocytes were infected with Ad.GFP (where Ad is adenovirus and GFP is green fluorescent protein), Ad.WT-Hsp20 (where WT is wild-type), and Ad.P20L-Hsp20 and subjected to simulated ischemia/reperfusion injury. | 0.000542884 | 2008 | HSPB6;PROSER3 | 19 | 35756950 | G | A |
rs121912438 | 17292357 | 6647 | SOD1 | umls:C0022116 | BeFree | Early vulnerability to ischemia/reperfusion injury in motor terminals innervating fast muscles of SOD1-G93A mice. | 0.12706742 | 2007 | SOD1 | 21 | 31667299 | G | C |
rs1799983 | 19481100 | 4846 | NOS3 | umls:C0022116 | BeFree | We conclude that microvascular reactivity, assessed by change in perfusion after temporary ischemia was not significantly different between the GG and GT genotypes of the eNOS G894T gene. | 0.128077243 | 2009 | NOS3 | 7 | 150999023 | T | G |
rs1883832 | 20682661 | 958 | CD40 | umls:C0022116 | GAD | [Our results suggest a potential implication of the CD40 rs1883832 C/T polymorphism in susceptibility to visual ischemic manifestations in individuals with biopsy-proven GCA.] | 0.002638474 | 2010 | CD40 | 20 | 46118343 | T | C |
GWASdb Annotation(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
GWASdb Snp Trait(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
Mapped by lexical matching(Total Items:0) |
---|
(Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
---|
(Waiting for update.) |
Chemical(Total Drugs:39) | |||||||||
---|---|---|---|---|---|---|---|---|---|
CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
C0022116 | amikacin | D000583 | 37517-28-5 | ischemia | MESH:D007511 | marker/mechanism | 9199746 | ||
C0022116 | amlodipine | D017311 | 88150-42-9 | ischemia | MESH:D007511 | therapeutic | 11002857 | ||
C0022116 | bisoprolol | D017298 | 66722-44-9 | ischemia | MESH:D007511 | therapeutic | 2967185 | ||
C0022116 | bivalirudin | C074619 | 128270-60-0 | ischemia | MESH:D007511 | therapeutic | 18436116 | ||
C0022116 | bleomycin | D001761 | 11056-06-7 | ischemia | MESH:D007511 | marker/mechanism | 2456930 | ||
C0022116 | carmustine | D002330 | 154-93-8 | ischemia | MESH:D007511 | marker/mechanism | 3340295 | ||
C0022116 | cisplatin | D002945 | 15663-27-1 | ischemia | MESH:D007511 | marker/mechanism | 2278719 | ||
C0022116 | diethylstilbestrol | D004054 | 56-53-1 | ischemia | MESH:D007511 | marker/mechanism | 10037391 | ||
C0022116 | dihydroergotamine | D004087 | 511-12-6 | ischemia | MESH:D007511 | marker/mechanism | 3139897 | ||
C0022116 | diltiazem | D004110 | 42399-41-7 | ischemia | MESH:D007511 | therapeutic | 1472086 | ||
C0022116 | fluorouracil | D005472 | 51-21-8 | ischemia | MESH:D007511 | marker/mechanism | 10023329 | ||
C0022116 | leucovorin | D002955 | 1958/5/9 | ischemia | MESH:D007511 | marker/mechanism | 10023329 | ||
C0022116 | gemcitabine | C056507 | 103882-84-4 | ischemia | MESH:D007511 | marker/mechanism | 15924070 | ||
C0022116 | indomethacin | D007213 | 53-86-1 | ischemia | MESH:D007511 | marker/mechanism | 8092206 | ||
C0022116 | labetalol | D007741 | 36894-69-6 | ischemia | MESH:D007511 | therapeutic | 2764457 | ||
C0022116 | methadone | D008691 | 76-99-3 | ischemia | MESH:D007511 | marker/mechanism | 4367894 | ||
C0022116 | methysergide | D008784 | 361-37-5 | ischemia | MESH:D007511 | marker/mechanism | 1663389 | ||
C0022116 | metoprolol | D008790 | 37350-58-6 | ischemia | MESH:D007511 | marker/mechanism | 2878675 | ||
C0022116 | minoxidil | D008914 | 38304-91-5 | ischemia | MESH:D007511 | therapeutic | 15167272 | ||
C0022116 | nicotine | D009538 | - | ischemia | MESH:D007511 | marker/mechanism | 19559087 | ||
C0022116 | nimodipine | D009553 | 66085-59-4 | ischemia | MESH:D007511 | therapeutic | 11182480 | ||
C0022116 | nisoldipine | D015737 | 63675-72-9 | ischemia | MESH:D007511 | therapeutic | 8742913 | ||
C0022116 | nitroprusside | D009599 | 15078-28-1 | ischemia | MESH:D007511 | therapeutic | 8600619 | ||
C0022116 | norepinephrine | D009638 | 51-41-2 | ischemia | MESH:D007511 | marker/mechanism | 3706779 | ||
C0022116 | octreotide | D015282 | 83150-76-9 | ischemia | MESH:D007511 | therapeutic | 18624922 | ||
C0022116 | pasireotide | C517782 | - | ischemia | MESH:D007511 | therapeutic | 18624922 | ||
C0022116 | peginterferon alfa-2b | C417083 | - | ischemia | MESH:D007511 | marker/mechanism | 16169782 | ||
C0022116 | propranolol | D011433 | 525-66-6 | ischemia | MESH:D007511 | marker/mechanism | 15701768 | ||
C0022116 | propylthiouracil | D011441 | 51-52-5 | ischemia | MESH:D007511 | marker/mechanism | 15701768 | ||
C0022116 | epoprostenol | D011464 | 35121-78-9 | ischemia | MESH:D007511 | marker/mechanism | 2433921 | ||
C0022116 | ramipril | D017257 | 87333-19-5 | ischemia | MESH:D007511 | therapeutic | 12022243 | ||
C0022116 | ribavirin | D012254 | 36791-04-5 | ischemia | MESH:D007511 | marker/mechanism | 16169782 | ||
C0022116 | riluzole | D019782 | 1744-22-5 | ischemia | MESH:D007511 | therapeutic | 10067977 | ||
C0022116 | rosiglitazone | C089730 | - | ischemia | MESH:D007511 | therapeutic | 18158644 | ||
C0022116 | tacrolimus | D016559 | 109581-93-3 | ischemia | MESH:D007511 | therapeutic | 12892836 | ||
C0022116 | temazepam | D013693 | 846-50-4 | ischemia | MESH:D007511 | marker/mechanism | 8181625 | ||
C0022116 | troglitazone | C057693 | 97322-87-7 | ischemia | MESH:D007511 | therapeutic | 12468449 | ||
C0022116 | vigabatrin | D020888 | 60643-86-9 | ischemia | MESH:D007511 | marker/mechanism | 8164764 | ||
C0022116 | vinblastine | D014747 | 865-21-4 | ischemia | MESH:D007511 | marker/mechanism | 2456930 |
FDA approved drug and dosage information(Total Drugs:2) | ||||||||
---|---|---|---|---|---|---|---|---|
DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
MESH:D007511 | sabril | vigabatrin | 500MG | TABLET;ORAL | Prescription | None | Yes | Yes |
MESH:D007511 | sabril | vigabatrin | 500MG/PACKET | FOR SOLUTION;ORAL | Prescription | AA | Yes | Yes |
FDA labeling changes(Total Drugs:2) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
MESH:D007511 | 10/26/2013 | sabril | vigabatrin | Refractory complex partial seizures (rCPS) | Approved as adjunctive therapy for pediatric patients 10 years and older with rCPS for whom the potential benefits outweigh the risk of vision loss. Sabril is not a first line agent for rCPS Safety and effectiveness for pediatric patients less than 10 years with refractory rCPS have not been established Pooled data from 3 controlled trials in pediatric patients demonstrated that 6% (10/165) of Sabril patients experienced somnolence compared to 5% (5/104) of placebo patients. In those same studies, 10% (17/165) of Sabril patients experienced fatigue compared to 7% (7/104) of placebo patients; 47% (77/163) of Sabril patients versus 19% (19/102) of placebo patients gained greater than or equal to 7% of baseline body weight Adverse reactions (ARs) in the pediatric population were similar to those reported in adults. Overall, ARs in pediatric patients 10-16 years included increased weight, upper respiratory tract infection, tremor, fatigue, aggression and diplopia Information on weight based dosing, dosing in renal impairment, safety information and clinical trials | Labeling | - | - | B,P | - | Lundbeck LLC | 3/10/2013 | FALSE' |
MESH:D007511 | 10/26/2013 | sabril | vigabatrin | Refractory complex partial seizures (rCPS) | Approved as adjunctive therapy for pediatric patients 10 years and older with rCPS for whom the potential benefits outweigh the risk of vision loss. Sabril is not a first line agent for rCPS Safety and effectiveness for pediatric patients less than 10 years with refractory rCPS have not been established Pooled data from 3 controlled trials in pediatric patients demonstrated that 6% (10/165) of Sabril patients experienced somnolence compared to 5% (5/104) of placebo patients. In those same studies, 10% (17/165) of Sabril patients experienced fatigue compared to 7% (7/104) of placebo patients; 47% (77/163) of Sabril patients versus 19% (19/102) of placebo patients gained greater than or equal to 7% of baseline body weight Adverse reactions (ARs) in the pediatric population were similar to those reported in adults. Overall, ARs in pediatric patients 10-16 years included increased weight, upper respiratory tract infection, tremor, fatigue, aggression and diplopia Information on weight based dosing, dosing in renal impairment, safety information and clinical trials | Labeling | - | - | B,P | - | Lundbeck LLC | 3/10/2013 | FALSE' |